Rakovina Targets Growth Opportunities at JPM Partnering Week
Rakovina Therapeutics will use JPM Week 2026 to court partners and investors on the back of new preclinical data...
No videos found.
Inventiva Reveals Its Q3 2025 Financial Portfolio Report
Inventiva reported €97.6 million in cash and cash equivalents as of September 30, 2025, €4.5 million in revenue for...
Nanobiotix Q3 2025 Financial Update & 2026 Clinical Outlook
Nanobiotix has closed a non-dilutive royalty financing with Healthcare Royalty for up to $71 million, securing $50 million upfront...
Cellectar & Ionetix Forge Powerful Alpha Therapy Supply Deal
Cellectar Biosciences has signed a multi-year supply agreement with IONETIX for cGMP-grade actinium-225 and astatine-211 to support clinical development...
Vyne Therapeutics and Yarrow Bioscience Announce Merger
Vyne Therapeutics and Yarrow Bioscience will merge in an all-stock transaction to form Yarrow Bioscience, which plans to trade...
Sagimet, TAPI Announce Global Resmetirom API License Deal
Sagimet Biosciences has secured a global, exclusive license from Teva’s TAPI Technology & API Services to use innovative forms...
Veru Reports FY2025 Financial Results & Clinical Progress
Veru has secured FDA feedback that clarifies a regulatory path for enobosarm as an adjunct to GLP-1 receptor agonists...
Europe Has World-Class Biotech Science. This Is the Law Admitting Everything Else Is Broken.
The company had done everything right. Strong translational science. Clean Phase 2 data. Positive scientific advice from the EMA....
Compliance and Creativity Converge as MLR Reframes Modern Medical Content
In the ever-evolving landscape of the pharmaceutical and MedTech industries, balancing compliance with creativity is a crucial challenge. This...
Oncotelic Unveils Revolutionary DeciParticle™ Nanomedicine
Sapu Nano, a 45% owned joint venture of Oncotelic Therapeutics, reported new data at the 2025 San Antonio Breast...